Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients

od Santini, Valeria, Fenaux, Pierre, Giagounidis, Aristoteles, Platzbecker, Uwe, List, Alan F., Haferlach, Torsten, Zhong, Jim, Wu, Chengqing, Mavrommatis, Konstantinos, Beach, C. L., MacBeth, Kyle J., Almeida, Antonio
Izdano u Leukemia (2020)

Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancer

od Babiker, Hani M., Milhem, Mohammed, Aisner, Joseph, Edenfield, William, Shepard, Dale, Savona, Michael, Iyer, Swaminathan, Abdelrahim, Maen, Beach, C. L., Skikne, Barry, Laille, Eric, Tsai, Kao-Tai, Ho, Thai
Izdano u Cancer Chemother Pharmacol (2020)

Correction to: Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancer

od Babiker, Hani M., Milhem, Mohammed, Aisner, Joseph, Edenfield, William, Shepard, Dale, Savona, Michael, Iyer, Swaminathan, Abdelrahim, Maen, Beach, C. L., Skikne, Barry, Laille, Eric, Tsai, Kao-Tai, Ho, Thai
Izdano u Cancer Chemother Pharmacol (2020)

Effects of azacitidine compared with conventional care regimens in elderly (≥75 years) patients with higher-risk myelodysplastic syndromes

od Seymour, John F., Fenaux, Pierre, Silverman, Lewis R., Mufti, Ghulam J., Hellström-Lindberg, Eva, Santini, Valeria, List, Alan F., Gore, Steven D., Backstrom, Jay, McKenzie, David, Beach, C.L.
Izdano 2010

Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure

od Prébet, Thomas, Gore, Steven D., Esterni, Benjamin, Gardin, Claude, Itzykson, Raphael, Thepot, Sylvain, Dreyfus, François, Rauzy, Odile Beyne, Recher, Christian, Adès, Lionel, Quesnel, Bruno, Beach, C.L., Fenaux, Pierre, Vey, Norbert
Izdano u J Clin Oncol (2011)

Population Pharmacokinetics of an Anti-PD-L1 Antibody, Durvalumab in Patients with Hematologic Malignancies

od Ogasawara, Ken, Newhall, Kathryn, Maxwell, Stephen E., Dell’Aringa, Justine, Komashko, Vitalina, Kilavuz, Nurgul, Delarue, Richard, Czuczman, Myron, Sternas, Lars, Rose, Shelonitda, Beach, C. L., Novick, Steven, Zhou, Simon, Palmisano, Maria, Li, Yan
Izdano u Clin Pharmacokinet (2019)

Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care

od Döhner, Hartmut, Dolnik, Anna, Tang, Lin, Seymour, John F., Minden, Mark D., Stone, Richard M., del Castillo, Teresa Bernal, Al-Ali, Haifa Kathrin, Santini, Valeria, Vyas, Paresh, Beach, C. L., MacBeth, Kyle J., Skikne, Barry S., Songer, Steve, Tu, Nora, Bullinger, Lars, Dombret, Hervé
Izdano u Leukemia (2018)

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

od Fenaux, Pierre, Mufti, Ghulam J, Hellstrom-Lindberg, Eva, Santini, Valeria, Finelli, Carlo, Giagounidis, Aristoteles, Schoch, Robert, Gattermann, Norbert, Sanz, Guillermo, List, Alan, Gore, Steven D, Seymour, John F, Bennett, John M, Byrd, John, Backstrom, Jay, Zimmerman, Linda, McKenzie, David, Beach, C L, Silverman, Lewis R
Izdano 2009

Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens

od Seymour, John F., Döhner, Hartmut, Butrym, Aleksandra, Wierzbowska, Agnieszka, Selleslag, Dominik, Jang, Jun Ho, Kumar, Rajat, Cavenagh, James, Schuh, Andre C., Candoni, Anna, Récher, Christian, Sandhu, Irwindeep, del Castillo, Teresa Bernal, Al-Ali, Haifa Kathrin, Falantes, Jose, Stone, Richard M., Minden, Mark D., Weaver, Jerry, Songer, Steve, Beach, C. L., Dombret, Hervé
Izdano u BMC Cancer (2017)

Role of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem-Cell Transplantation in Older Patients With De Novo Myelodysplastic Syndromes: An International Collaborative D...

od Koreth, John, Pidala, Joseph, Perez, Waleska S., Deeg, H. Joachim, Garcia-Manero, Guillermo, Malcovati, Luca, Cazzola, Mario, Park, Sophie, Itzykson, Raphael, Ades, Lionel, Fenaux, Pierre, Jadersten, Martin, Hellstrom-Lindberg, Eva, Gale, Robert Peter, Beach, C.L., Lee, Stephanie J., Horowitz, Mary M., Greenberg, Peter L., Tallman, Martin S., DiPersio, John F., Bunjes, Donald, Weisdorf, Daniel J., Cutler, Corey
Izdano 2013

International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts

od Dombret, Hervé, Seymour, John F., Butrym, Aleksandra, Wierzbowska, Agnieszka, Selleslag, Dominik, Jang, Jun Ho, Kumar, Rajat, Cavenagh, James, Schuh, Andre C., Candoni, Anna, Récher, Christian, Sandhu, Irwindeep, Bernal del Castillo, Teresa, Al-Ali, Haifa Kathrin, Martinelli, Giovanni, Falantes, Jose, Noppeney, Richard, Stone, Richard M., Minden, Mark D., McIntyre, Heidi, Songer, Steve, Lucy, Lela M., Beach, C. L., Döhner, Hartmut
Izdano u Blood (2015)

Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes

od Garcia-Manero, Guillermo, Santini, Valeria, Almeida, Antonio, Platzbecker, Uwe, Jonasova, Anna, Silverman, Lewis R., Falantes, Jose, Reda, Gianluigi, Buccisano, Francesco, Fenaux, Pierre, Buckstein, Rena, Diez Campelo, Maria, Larsen, Stephen, Valcarcel, David, Vyas, Paresh, Giai, Valentina, Olíva, Esther Natalie, Shortt, Jake, Niederwieser, Dietger, Mittelman, Moshe, Fianchi, Luana, La Torre, Ignazia, Zhong, Jianhua, Laille, Eric, Lopes de Menezes, Daniel, Skikne, Barry, Beach, C. L., Giagounidis, Aristoteles
Izdano u J Clin Oncol (2021)